Browsing by Author "Jain, Ankur"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Glucororticoid Receptor Alternative Splicing: Key Players and Role in TM and Glaucoma(2012-12-01) Jain, Ankur; Clark, Abbot F.Elevated intraocular pressure (IOP) is the primary risk factor in glaucoma, a leading cause of irreversible blindness. Various morphological and biochemical changes in the trabecular meshwork (TM) appear to be responsible for blocking aqueous humor outflow, thereby elevating IOP. Glucocorticoids (GCs) are known to induce ocular hypertension and other biochemical changes associated with glaucoma. Interestingly, there are differences in steroid responsiveness among the population, with 40% people known as responders who significantly elevate IOP upon GC treatment and others being classified as nonresponders. The steroid-responders are at higher risk of developing primary open angle glaucoma (POAG) as compared to the steroid nonresponders. At the same time, almost all POAG patients are moderate to high steroid responders. GC responsiveness is regulated by the relative ratios of the GC activated transcription factor GC receptor alpha (GRα) and the alternatively spliced dominant negative regulator isoform of this receptor (GRβ). Glaucomatous TM cell strains have a higher GRα/GRβ ratio compared to normal TM cells making them more sensitive to GCs. Regulation of the GRα/GRβ splicing is not very well documented. The role of splicing factors that regulate spliceosome assembly seems to be one of the key factors regulating the process of alternative splicing. We have shown that the relative levels of the different serine-arginine (SR) proteins (SRps) in the TM regulate the differential expression of the two alternatively spliced isoforms of GR, GRα and GRβ and that expression of these SR proteins regulates GC responsiveness in TM cells. In addition, we evaluated a special class of compounds (thailanstatins or TSTs) and found them to modulate this splicing process to enhance GRβ levels in TM cells. These splicing modulators increased GRβ/GRα in TM, decreased GC response and provide potential glaucoma therapeutic agents.Item Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma(Springer Nature Limited, 2024-03-24) Patil, Shruti V.; Kaipa, Balasankara R.; Ranshing, Sujata; Sundaresan, Yogapriya; Millar, J. Cameron; Nagarajan, Bhavani; Kiehlbauch, Charles; Zhang, Qihong; Jain, Ankur; Searby, Charles C.; Scheetz, Todd E.; Clark, Abbot F.; Sheffield, Val C.; Zode, Gulab S.Mutations in myocilin (MYOC) are the leading known genetic cause of primary open-angle glaucoma, responsible for about 4% of all cases. Mutations in MYOC cause a gain-of-function phenotype in which mutant myocilin accumulates in the endoplasmic reticulum (ER) leading to ER stress and trabecular meshwork (TM) cell death. Therefore, knocking out myocilin at the genome level is an ideal strategy to permanently cure the disease. We have previously utilized CRISPR/Cas9 genome editing successfully to target MYOC using adenovirus 5 (Ad5). However, Ad5 is not a suitable vector for clinical use. Here, we sought to determine the efficacy of adeno-associated viruses (AAVs) and lentiviruses (LVs) to target the TM. First, we examined the TM tropism of single-stranded (ss) and self-complimentary (sc) AAV serotypes as well as LV expressing GFP via intravitreal (IVT) and intracameral (IC) injections. We observed that LV_GFP expression was more specific to the TM injected via the IVT route. IC injections of Trp-mutant scAAV2 showed a prominent expression of GFP in the TM. However, robust GFP expression was also observed in the ciliary body and retina. We next constructed lentiviral particles expressing Cas9 and guide RNA (gRNA) targeting MYOC (crMYOC) and transduction of TM cells stably expressing mutant myocilin with LV_crMYOC significantly reduced myocilin accumulation and its associated chronic ER stress. A single IVT injection of LV_crMYOC in Tg-MYOC(Y437H) mice decreased myocilin accumulation in TM and reduced elevated IOP significantly. Together, our data indicates, LV_crMYOC targets MYOC gene editing in TM and rescues a mouse model of myocilin-associated glaucoma.